Aura Biosciences, Inc.
AURA
$6.55
$0.081.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.58% | 8.19% | 21.54% | 22.45% | 14.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.71% | 30.13% | 12.20% | 13.39% | 12.26% |
| Operating Income | -25.71% | -30.13% | -12.20% | -13.39% | -12.26% |
| Income Before Tax | -32.62% | -39.70% | -17.35% | -13.43% | -11.14% |
| Income Tax Expenses | -- | -60.87% | -82.48% | -- | -- |
| Earnings from Continuing Operations | -32.86% | -39.47% | -16.73% | -13.67% | -11.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.86% | -39.47% | -16.73% | -13.67% | -11.14% |
| EBIT | -25.71% | -30.13% | -12.20% | -13.39% | -12.26% |
| EBITDA | -26.18% | -30.61% | -12.50% | -13.77% | -12.38% |
| EPS Basic | -13.47% | -37.59% | -4.38% | 12.60% | 15.10% |
| Normalized Basic EPS | -13.29% | -37.79% | -3.93% | 12.77% | 15.09% |
| EPS Diluted | -13.47% | -37.59% | -4.38% | 12.60% | 15.10% |
| Normalized Diluted EPS | -13.29% | -37.79% | -3.93% | 12.77% | 15.09% |
| Average Basic Shares Outstanding | 17.09% | 1.36% | 11.84% | 30.06% | 30.89% |
| Average Diluted Shares Outstanding | 17.09% | 1.36% | 11.84% | 30.06% | 30.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |